Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy

Journal of Magnetic Resonance Imaging

Volumn 32, Issue 2, 2010, Pages 409-417

  Wang, Hesheng ^a,b   Fei, Baowei ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Case Western Reserve University   (United States)

^c Emory University   (United States)

Author keywords

Apparent diffusion coefficients (ADC); Diffusion weighted MRI; Efficacy assessment; Photodynamic therapy; Prostate cancer; Treatment monitoring

Indexed keywords

PHOTOSENSITIZING AGENT; PROSTATE SPECIFIC ANTIGEN; SILICON PHTHALOCYANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ILLUMINATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DIFFUSION; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955387243     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22247     Document Type: Article

References (35)

1. Triesscheijn M, Baas P, Schellens JH, et al. Photodynamic therapy in oncology. Oncologist 2006;11:1034-1044.
2. Schneider LA, Hinrichs R, Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol 2008;26:464-476.
3. Huang Z, Chen Q, Dole KC, et al. The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues-in vivo study in a canine model. Photochem Photobiol Sci 2007;6:1318-1324. (Pubitemid 350191104)
4. Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs 2008;2008:276109.
5. Juarranz A, Jaen P, Sanz-Rodriguez F, et al. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008;10:148-154.
6. Fei B, Wang H, Meyers JD, et al. High-field magnetic resonance imaging of the response of human prostate cancer to Pc 4-based photodynamic therapy in an animal model. Lasers Surg Med 2007;39:723-730. (Pubitemid 350086407)
7. Jiang Q, Knight RA, Chopp M, et al. 1H magnetic resonance imaging of normal brain tissue response to photodynamic therapy. Neurosurgery 1991;29:538-546.
8. Dodd NJ, Moore JV, Poppitt DG, et al. In vivo magnetic resonance imaging of the effects of photodynamic therapy. Br J Cancer 1989;60:164-167.
9. Liu YH, Hawk RM, Ramaprasad S. In-vivo relaxation-time measurements on a murine tumor-model - prolongation of T-1 after photodynamic therapy. Magn Reson Imaging 1995;13:251-258.
10. Winsborrow BG, Grondey H, Savoie H, et al. Magnetic resonance imaging evaluation of photodynamic therapy-induced hemorrhagic necrosis in the murine M1 tumor model. Photochem Photobiol 1997;66:847-852. (Pubitemid 127470126)
11. Kennedy SD, Szczepaniak LS, Gibson SL, et al. Quantitative MRI of Gd-Dtpa uptake in tumors - response to photodynamic therapy. Magn Reson Med 1994;31:292-301.
12. Trachtenberg J, Weersink RA, Davidson SRH, et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008;102:556-562.
13. Haider MA, Davidson SR, Kale AV, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007;244:196-204.
14. Gross S, Gilead A, Scherz A, et al. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003;9:1327-1331. (Pubitemid 37279859)
15. Bremner JC, Wood SR, Bradley JK, et al. 31P magnetic resonance spectroscopy as a predictor of efficacy in photodynamic therapy using differently charged zinc phthalocyanines. Br J Cancer 1999;81:616-621.
16. Ramaprasad S, Ripp E, Missert J, et al. In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model. Curr Drug Discov Technol 2007;4:126-132.
17. Plaks V, Koudinova N, Nevo U, et al. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia 2004;6:224-233. (Pubitemid 38657078)
18. Huang Z, Haider MA, Kraft S, et al. Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg Med 2006;38:672-681.
19. Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004;232:685-692. (Pubitemid 39100249)
20. Fei B, Wang H, Wu C, et al. Choline PET for monitoring early tumor response to photodynamic therapy. J Nucl Med 2010;51:130-138.
21. Fei B, Wang H, Wu C, et al. Choline molecular imaging with small-animal PET for monitoring tumor cellular response to photodynamic therapy of cancer. Proc SPIE 2009;726211.
22. Fei B, Wang H, Muzic RF Jr, et al. Deformable and rigid registration of MRI and microPET images for photodynamic therapy of cancer in mice. Med Phys 2006;33:753-760.
23. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-6052. (Pubitemid 24378626)
24. Oleinick NL, Antunez AR, Clay ME, et al. New phthalocyanine photosensitizers for photodynamic therapy. Photochem Photobiol 1993;57:242-247.
25. Colussi VC, Feyes DK, Mulvihill JW, et al. Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem Photobiol 1999;69:236-241. (Pubitemid 129606912)
26. Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161:401-407. (Pubitemid 17173295)
27. Wang H, Fei B. A modified fuzzy C-means classification method using a multiscale diffusion filtering scheme. Med Image Anal 2009;13:193-202.
28. Inan N, Arslan A, Akansel G, et al. Diffusion-weighted imaging in the differential diagnosis of cystic lesions of the pancreas. AJR Am J Roentgenol 2008;191:1115-1121.
29. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6:135-143.
30. Hoehn-Berlage M, Tolxdorff T, Bockhorst K, et al. In vivo NMR T2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn Reson Imaging 1992;10:935-947.
31. Xue LY, Chiu SM, Azizuddin K, et al. The death of human cancer cells following photodynamic therapy: apoptosis competence is necessary for Bcl-2 protection but not for induction of autophagy. Photochem Photobiol 2007;83:1016-1023.
32. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002;1:1-21. (Pubitemid 37069701)
33. Cui Y, Zhang XP, Sun YS, et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248:894-900.
34. Harry VN, Semple SI, Gilbert FJ, et al. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111:213-220.
35. Miller JD, Baron ED, Scull H, et al. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol 2007;224:290-299.